Projects per year
Personal profile
Personal profile
Dr. Jenny C. Chang is the Director of Houston Methodist Cancer Center and Emily Herrmann Chair in Cancer Research in Houston, Texas. She obtained her medical degree at Cambridge University in England, and then completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research in the United Kingdom. She was also awarded a research doctorate from the University of London. Her recent work has focused on the intrinsic therapy resistance of cancer stem cells, which has led to several publications and international presentations. Dr. Chang’s clinical research aims to evaluate novel biologic agents in breast cancer patients.
Research interests
Dr. Chang has worked in the field of tumor-initiating cells for more than ten years. After her discovery that tumor-initiating cells are chemo-resistant, and that targeting the EGFR/HER2 pathway can decrease this subpopulation, Dr. Chang has played a key role in demonstrating some of the limitations and mechanisms of tumor-initiating cells (Creighton et al., 2009; Li et al., 2008). Her work is now focused on the mechanisms that regulate TICs, as well as initiating and planning clinical trials that target this critical tumor initiating subpopulation. She is also interested in characterizing the cross-talk between these different pathways that may lead to mechanisms of resistance, and has identified some of the chief regulatory pathways involved in TIC self-renewal. She is a world-renown clinical investigator, credited as one of the first to describe intrinsic chemo-resistance of tumor-initiating cells.
Education/Academic qualification
MD, University of Cambridge
Aug 1 1986 → Dec 18 1990
Award Date: Dec 18 1990
Research Doctorate, University of London
External positions
Professor of Medicine, Weill Cornell Medical College, Cornell University
Research Area Keywords
- Cancer
- Systems Medicine & Bioinformatics
- Clinical Translation & Trials
Free-text keywords
- Cancer
- Stem cells
- Breast cancer
- High throughput
Fingerprint
Dive into the research topics where Jenny C. Chang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Abdelrahim, M., Bernicker, E. H., Chang, J. C., Darcourt, J., Heyne, K., Niravath, P. A., Singh, M. & Zhang, J.
9/10/21 → …
Project: Clinical Trial
-
Phase 3_Trastuzumab Deruxtecan T-DXd; DS-8201a_HER2-positiveBreastCancer_DS8201-A-U305NSABP B-60
Chang, J. C., Darcourt, J., Geyer, C. E. & Niravath, P. A.
7/30/21 → …
Project: Clinical Trial
-
Phase II_FulvestrantAbemaciclib_ERHer2-metastaticBreastCancer_HMRIEli Lilly
Chang, J. C., Darcourt, J., Geyer, C. E. & Niravath, P. A.
7/15/21 → …
Project: Clinical Trial
-
Converting HR Breast Cancer Into an Individualized Vaccine
Chang, J. C., Darcourt, J., Geyer, C. E. & Niravath, P. A.
5/26/21 → …
Project: Clinical Trial
Research output
-
Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma
Li, Z., Liu, H., He, J., Wang, Z., Yin, Z., You, G., Wang, Z., Davis, R. E., Lin, P., Bergsagel, P. L., Manasanch, E. E., Wong, S. T. C., Esnaola, N. F., Chang, J. C., Orlowski, R. Z., Yi, Q. & Yang, J., Jan 5 2021, In: Cell Metabolism. 33, 1, p. 78-93.e7Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations -
Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic
Darcourt, J. G., Aparicio, K., Dorsey, P. M., Ensor, J. E., Zsigmond, E. M., Wong, S. T., Ezeana, C. F., Puppala, M., Heyne, K. E., Geyer, C. E., Phillips, R. A., Schwartz, R. L. & Chang, J. C., Jan 1 2021, In: JCO oncology practice. 17, 1, p. e36-e43Research output: Contribution to journal › Article › peer-review
Open Access16 Scopus citations -
ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer
Koca, E., Niravath, P. A., Ensor, J., Patel, T. A., Li, X., Hemati, P., Wong, H., Qian, W., Boone, T., Zhao, J., Ramshesh, P. V., Cohen, A. L., Murthy, A., Nair, S., Darcourt, J. G., Belcheva, A., Kaklamani, V. G. & Chang, J. C. N., Jul 2021, In: Breast Cancer Research and Treatment. 188, 2, p. 433-439 7 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer
Anand, K., Niravath, P., Patel, T., Ensor, J., Rodriguez, A., Boone, T., Wong, S. T. & Chang, J. C., Jun 2021, In: Clinical Breast Cancer. 21, 3, p. 199-204 6 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
for the fRida Trial Investigators, Nov 2021, In: Breast Cancer Research and Treatment. 190, 2, p. 265-275 11 p.Research output: Contribution to journal › Article › peer-review
Open Access